Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1

Anesthesia and Analgesia

Volumn 87, Issue 5, 1998, Pages 985-988

  Kozek Langenecker, Sibylle A ^a   Wanzel, Oliver ^a   Berger, Reinhard ^a   Kettner, Stephan C ^a   Coraim, Farad ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HEPARIN IMMUNO; PLACEBO; PROSTAGLANDIN E1; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; HUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALPROSTADIL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; BLOOD PRESSURE; CARDIOPULMONARY BYPASS; FEMALE; HEPARIN; HUMANS; MALE; PROTHROMBIN; THROMBIN;

EID: 0031754365     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199811000-00001     Document Type: Article

References (25)

1. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
2. Boisclair MD, Lane DA, Philippou H, et al. Mechanism of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
3. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96: 3534-41.
4. Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997;113:576-84.
5. Speekenbrink RGH, Wildevuur CRH, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 1996;112:523-30.
6. Slaughter TF, LeBleu TH, Douglas JM, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6.
7. Knudsen L, Hasenkam JM, Kure HH, et al. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass. Thromb Res 1996;84:45-54.
8. Lu H, Du Built C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Hemost 1994;72:438-43.
9. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:518-27.
10. Dietrich W, Spannagl M, Schramm W, et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505-14.
11. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
12. Kapplmayer J, Bernabei A, Edmunds LH, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72:1075-81.
13. 1 inhibit monocyte procoagulant activity in vitro. Blood 1991;78:382-6.
14. Walsh PN. Different requirements for intrinsic factor-Xa form-ing activity and platelet factor 3 activity and their relationship to platelet aggregation and secretion. Br J Haematol 1978;40:311-31.
15. Hirsh J, Fuster V. Guide to anticoagulant therapy: part 1. Circulation 1994;89:1449-68.
16. 1 inhibits platelet decrease after massive blood transfusions during major surgery: influence on coagulation cascade? J Trauma 1997;42:525-31.
17. 1: the endogenous physiological regulator of platelet mediated blood coagulation. Prostaglandins Leukot Essent Fatty Acids 1989;35:189-95.
18. 1 on platelet decrease in the heart-lung machine. Haemostasis 1973;2:294-303.
19. 1 during in vitro simulation of cardiopulmonary bypass. Circ Res 1979;44:350-7.
20. El-Gatit A, Al-Khaja N, Belboul A, et al. Effects of alprostadil infusion during extracorporeal circulation on blood rheology and postoperative blood loss. Vasc Surg 1992;26:521-8.
21. 1 in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 1983;35:406-14.
22. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-41.
23. Hayashida N, Isomura T, Sato T, et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997;114:261-9.
24. Royston D. High-dose aprotinin therapy: A review of the first five years' experience. J Cardiothorac Vase Anesth 1992;6:76-100.
25. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforsch 1983;33:479-94.